Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/82067
Full metadata record
DC FieldValueLanguage
dc.creatorJoana Matos
dc.creatorFilipa P da Cruz
dc.creatorElia Cabrita
dc.creatorJiri Gut
dc.creatorFatima Nogueira
dc.creatorVirgilio E do Rosario
dc.creatorRui Moreira
dc.creatorPhilip J Rosenthal
dc.creatorMiguel Prudencio
dc.creatorPaula Gomes
dc.date.accessioned2019-02-06T04:26:39Z-
dc.date.available2019-02-06T04:26:39Z-
dc.date.issued2012
dc.identifier.issn0066-4804
dc.identifier.othersigarra:89178
dc.identifier.urihttps://repositorio-aberto.up.pt/handle/10216/82067-
dc.description.abstractNovel conjugates of the antimalarial drug primaquine (compound 1) with ferrocene, named primacenes, have been synthesized and screened for their activities against blood stage and liver stage malaria in vitro and host-vector transmission in vivo. Both transmission-blocking and blood-schizontocidal activities of the parent drug were conserved only in primacenes bearing a basic aliphatic amine group. Liver stage activity did not require this structural feature, and all metallocenes tested were comparable to or better than primaquine in this regard. Remarkably, the replacement of primaquine's aliphatic chain by hexylferrocene, as in compound 7, led to a similar to 45-fold-higher level activity against liver stage parasitemia than that of primaquine.
dc.language.isoeng
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectMedicina básica
dc.subjectBasic medicine
dc.titleNovel Potent Metallocenes against Liver Stage Malaria
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoFaculdade de Ciências
dc.identifier.doi10.1128/aac.05345-11
dc.identifier.authenticusP-002-CPH
dc.subject.fosCiências médicas e da saúde::Medicina básica
dc.subject.fosMedical and Health sciences::Basic medicine
Appears in Collections:FCUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
89178.pdf675.49 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons